Landmark deal paves way for cheaper HIV protection jab
Summary
A new HIV prevention drug called Lenacapavir, which is administered by injection, will be available at a much lower cost in over 100 low-income countries by 2027. This drug aims to provide greater access to HIV protection and help reduce new infections globally, especially in vulnerable populations. The deal was made possible by collaborations among the Clinton Foundation, the Gates Foundation, and other organizations.Key Facts
- Lenacapavir is a new HIV prevention drug approved by the World Health Organization.
- The drug will be available at $40 per person annually in over 120 low- and middle-income countries by 2027.
- The current cost of Lenacapavir is $28,000 per person annually.
- It is taken twice a year and provides six months of protection against HIV.
- The drug works by stopping the virus from replicating inside cells.
- The Clinton Foundation, Gates Foundation, and other groups negotiated the reduced price.
- Lenacapavir has shown promising results in trials, including a 100% success rate reported by Gilead.
- Increasing access to Lenacapavir to just 4% of the population could prevent up to 20% of new HIV infections.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
